Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
CI

NASDAQ · CING

Cingulate Inc.

Healthcare · Biotechnology

$4.89

Up+$0.14 (+2.95%)

Updated Oct 7, 2026, 5:21 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
23.43M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$3.16 – $11.89
Volume
111.67K
Avg. volume
177.3K

Price performance · CING

CING price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

CING closed at $4.89 after 21 trading sessions, down 5.78% for the selected period.

Last close
$4.89
Period change
-5.78%
Period low
$4.75
Period high
$5.24
Daily close
View OHLC price history
CING OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$4.75$5.00$4.75$4.89111.67K
Oct 5, 2026$4.82$4.905$4.63$4.75139.94K
Oct 2, 2026$4.79$4.9036$4.705$4.7652.62K
Oct 1, 2026$4.95$4.95$4.735$4.7548.98K
Sep 30, 2026$4.91$5.02$4.82$4.9566.81K
Sep 29, 2026$4.88$4.97$4.8368$4.90566.84K
Sep 28, 2026$4.97$4.97$4.59$4.82171.96K
Sep 25, 2026$5.01$5.12$4.80$4.83149.48K
Sep 24, 2026$5.015$5.07$4.81$5.0682.48K
Sep 23, 2026$5.10$5.22$4.93$4.98119.52K
Sep 22, 2026$5.26$5.3503$5.125$5.14578.63K
Sep 21, 2026$5.27$5.48$5.21$5.2375.49K
Sep 18, 2026$5.11$5.28$5.09$5.2483.19K
Sep 17, 2026$5.17$5.19$5.00$5.15124.4K
Sep 16, 2026$5.16$5.2097$5.09$5.0976.75K
Sep 15, 2026$5.16$5.21$5.03$5.1158.91K
Sep 14, 2026$5.00$5.19$4.80$5.17101.3K
Sep 11, 2026$5.22$5.28$5.02$5.0299.57K
Sep 10, 2026$5.17$5.41$5.155$5.17118.08K
Sep 9, 2026$5.24$5.40$5.16$5.2172.53K
Sep 8, 2026$5.09$5.28$5.05$5.1976.73K

Latest CING news

The latest Smart Investors Daily articles mentioning CING.

Stock researchCompany · Overview

CING research

Overview

Company profile and research snapshot.

Company profile

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$11.00
Implied upside
—
Analysts
—
CING recent ratings
DateFirmRatingTarget
Aug 24, 2026Roth CapitalBuy—
Aug 20, 2026Ascendiant CapitalBuy—
Jun 8, 2026Ascendiant CapitalBuy—
May 26, 2026HC Wainwright & Co.Buy—
Apr 8, 2026Ascendiant CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size PharmaKANSAS CITY, Kan., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today announced that Chairman and CEO Shane J. Schaffer and Chief Commercial Officer Bryan Downey will participate in two sessions

Benzinga · Aug 13, 2026

Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate

Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14) per share from the

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By